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Abstract Purpose: Presepsin is a
soluble fragment of the cluster-of-
differentiation marker protein 14
(CD14) involved in pathogen recog-
nition by innate immunity. We
evaluated the relation between its
circulating concentration, host
response, appropriateness of
antibiotic therapy, and mortality in
patients with severe sepsis. Meth-
ods: Plasma presepsin was
measured 1, 2, and 7 days after
enrollment of 997 patients with
severe sepsis or septic shock in the
multicenter Albumin Italian Outcome
Sepsis (ALBIOS) trial. They were
randomized to albumin or crystal-
loids. We tested with univariate and
adjusted models the association of
single measurements of presepsin or
changes over time with clinical
events, organ dysfunctions, appropri-
ateness of antibiotic therapy, and ICU
or 90-day mortality. Results: Pre-
sepsin concentration at baseline (946
[492–1,887] ng/L) increased with the
SOFA score, the number of prevalent
organ dysfunctions or failures, and
the incidence of new failures of the
respiratory, coagulation, liver, and
kidney systems. The concentration
decreased in ICU over 7 days in
patients with negative blood cultures,
and in those with positive blood cul-
tures and appropriate antibiotic
therapy; it increased with inappropri-
ate antibiotic therapy (p = 0.0009).
Baseline presepsin was independently
associated with, and correctly reclas-
sified, the risk of ICU and 90-day
mortality. Increasing concentrations
of presepsin from day 1 to day 2
predicted higher ICU and 90-day
mortality (adjusted p \ 0.0001 and
0.01, respectively). Albumin had no
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effect on presepsin concentration.
Conclusions: Presepsin is an early
predictor of host response and mor-
tality in septic patients. Changes in
concentrations over time seem to
reflect the appropriateness of antibi-
otic therapy.
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Introduction
Despite recent improvements, the incidence of sepsis in
hospitalized patients increases steadily and mortality rates
remain unacceptably high [1]. Recent failures with new
therapeutic strategies may stem from an incomplete
understanding of the underlying biology of sepsis [2].
Considering the variety of clinical phenotypes of severe
sepsis and septic shock, we need to understand more
accurately the pathophysiology of the disease to propose
more personalized therapies. In this context, circulating
biomarkers may improve early recognition, optimal
selection of appropriate therapies, and early risk stratifi-
cation [3–5].
Recognition of pathogen-associated molecular patterns
(PAMPs) from infecting microorganisms is mediated,
within the innate immune system, by proteins of the Toll-
like receptor (TLR) family [6]. The mechanism for the
recognition of lipopolysaccharide (LPS), a major PAMP
from the outer membrane of most Gram-negative bacteria,
involves accessory molecules that facilitate the presenta-
tion of LPS to the TLR4–MD2 complexes. CD14 is one of
these accessory proteins, expressed on the surface of
myelomonocytic cells and as a soluble molecule in the
circulation. CD14 is a broad-spectrum affinity component
of the innate immunity and detects a variety of ligands
associated also with Gram-positive bacteria, fungi, and
viruses [7, 8]. Acute inflammation may furthermore con-
tribute to CD14 up-regulation by tissues other than
monocytes [9]. During recognition of PAMPs by soluble
CD14, a 13-kDa fragment is formed, named sCD14 subtype
(sCD14-ST) or presepsin [10]. Presepsin is emerging as a
novel circulating marker of sepsis [10–15]. However, like
other candidates in sepsis, this biomarker needs to be val-
idated in large, multicenter studies with representative
populations [3].
In a pilot study, we previously showed that presepsin has
a better prognostic performance than procalcitonin in
patients with severe sepsis [16]. Here, we extend our
investigations on the clinical role of presepsin assay for
monitoring host response and appropriateness of antibiotic
therapy to a larger subpopulation of 997 patients enrolled in
a multicenter randomized clinical trial that assessed the
efficacy of albumin replacement in severe sepsis and septic
shock [17]. In particular, we aimed to elucidate (1) the
characteristics associated with increased presepsin levels,
(2) the clinical value of presepsin monitoring during the
disease, both in relation to the development of complica-
tions and to the treatment applied, and (3) prognostic
accuracy of presepsin for early and long-term outcomes.
Materials and methods
Study design
The Albumin Italian Outcome Sepsis (ALBIOS) study
was a multicenter, open-label trial that enrolled 1,818
patients with severe sepsis admitted to 100 intensive care
units (ICUs). The patients were randomly assigned to
receive either 20 % albumin and crystalloids or crystal-
loids alone, from randomization until day 28 or discharge
from the ICU, whichever came first. Study design,
inclusion and exclusion criteria, and main results were
published elsewhere [17] and are summarized in the
Supplementary Appendix.
The study was compliant with the 1975 Declaration of
Helsinki as revised in 2008, and approved first by the
Institutional Review Board of the Fondazione IRCCS Ca’
Granda-Ospedale Maggiore Policlinico, Milan, Italy
(coordinating center), and subsequently by the appropriate
institutional review boards of all the other participating
centers. Written informed consent was obtained for all
participants.
Sample collection and circulating presepsin
measurement
In a subset of 997 patients recruited in 40 centers that
participated in a predefined biomarkers substudy, venous
blood samples were serially collected 1, 2, and 7 days
after enrollment (or at ICU discharge, whichever came
first), centrifuged, and plasma was shipped on dry ice to a
central repository and stored at -70 C until being
assayed. Presepsin was measured with a chemilumines-
cent enzyme immunoassay (PATHFAST Presepsin,
Mitsubishi Chemical) by personnel blinded to patients’
characteristics. Intra-assay and inter-assay coefficients
were 4.4 % at 445 ng/L, and the limit of detection was
20 ng/L. Samples from a subset of 100 patients have
already been analyzed with the same method and included
in a preliminary publication [16].
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Definitions
Severe sepsis was defined as the presence of a proved or
suspected infection in at least one site, two or more signs
of systemic inflammatory reaction [18], and at least one
severe and acute sepsis-related organ dysfunction. Shock
at the time of randomization was defined as a score of 3 or
4 for the cardiovascular component of the Sequential
Organ Failure Assessment (SOFA) score [19]. New organ
failures were defined as a modification of each component
of the SOFA score during the study period to 3 or 4 from
a baseline of 0, 1, or 2. Acute kidney injury was defined
according to the risk, injury, failure, loss, and end-stage
kidney injury (RIFLE) criteria [20], based on the daily
incremental increases in serum creatinine from baseline.
Clinical resolution of the primary infection, if any, was
established by the treating physician according to stan-
dard clinical signs. Acquired secondary infections were
defined as new infections other than the primary infection
responsible for the development of severe sepsis, arising
during the study, based upon microbiological and clinical
assessments, and evaluated by the treating physician.
Appropriateness of antibiotic therapy was based on all
the pathogenic microorganisms isolated in either the site
or blood cultures. We considered the first-line empirical
antibiotic therapy as appropriate when all the microor-
ganisms isolated and reported as responsible for the
primary infection were susceptible to at least one antibi-
otic administered. For this purpose, we considered
antibiotic therapy empirically ongoing on day 1, i.e.,
about 24 h from enrollment. Antibiotic therapy was
considered inappropriate if applied after the first day of
enrollment, if it did not cover all the pathogens isolated,
or when pathogenic microorganisms were resistant.
Microorganism susceptibility to antibiotics was defined
by a local microbiologist who was unaware of the allo-
cation group or treatment applied.
Statistical methods
Categorical variables are presented as proportions, and
continuous variables as means (standard deviation) or
medians (Q1–Q3), based on the normality of distribution
by Kolmogorov–Smirnov test. Differences in clinical
characteristics according to tertiles of presepsin concen-
tration were analyzed with the Chi-square test or Fisher’s
exact test for categorical variables, and with the analysis
of variance or non-parametric Kruskal–Wallis test for
continuous variables.
We performed multivariable linear regression analysis
with backward elimination to identify the clinical deter-
minants independently associated with a high log-
transformed concentration of presepsin on day 1 (see
additional statistical methods in the Supplementary
Appendix). The concentrations of presepsin in clinical
subgroups were compared with the Kruskal–Wallis test
and trends across tertiles of presepsin concentration were
assessed with the Cochran–Armitage test or one-way
analysis of variance for categorical and continuous vari-
ables, respectively.
Changes in presepsin concentrations over time
according to survival status, treatment, and septic shock at
baseline were analyzed with two-way analysis of variance
for repeated measurements using log-transformed data.
Moreover, to account for the hierarchical nature of the data
(repeated measurements within patients) and to control
simultaneously for the possible confounding effects of the
different variables, multivariate multilevel linear regres-
sion models were performed [21] including as covariates
SOFA score, time, appropriateness of antibiotic therapy,
and an interaction term between time and appropriateness
of antibiotic therapy. All available measurements at each
time point for each patient were considered.
The relation between presepsin concentration and
mortality was first assessed with univariate logistic
models entering log-transformed concentration of the
biomarker as a continuous variable. A backward selection
method was applied to select the final model.
Prognostic discrimination of presepsin was evaluated
from the area under the receiver-operating characteristic
(ROC) curves (AUC), comparing multivariable models
with or without presepsin. The increased discriminative
value of presepsin for ICU and 90-day mortality was
assessed using the category-free net reclassification
improvement (cfNRI) and the integrated discrimination
improvement (IDI) index [22]. Changes in presepsin
concentrations over time were expressed as the difference
in log-transformed concentrations. Kaplan–Meier survival
curves were shown by tertiles of relative changes and
compared with the log-rank test. Both unadjusted and
covariate-adjusted logistic regression models were gen-
erated to assess potential associations between changes in
presepsin concentrations over time and mortality. A two-
sided p value of less than 0.05 was deemed statistically
significant.
Results
Clinical characteristics related to the presepsin
concentration
The concentration of presepsin on day 1 after randomi-
zation in the overall cohort of patients was 946
[492–1,887] ng/L (median [Q1–Q3], n = 958). Presepsin
was associated with several demographic, clinical,
hemodynamic, and laboratory variables (Table 1). Mul-
tiple linear regression analysis showed the strongest
association of higher presepsin concentrations, by
decreasing order of t value, with high serum creatinine
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(standardized beta coefficient = 0.34, p \ 0.0001) and
bilirubin (0.20, p \ 0.0001), low hemoglobin (-0.13,
p \ 0.0001), older age (0.12, p \ 0.0001), reduced urine
output (-0.10, p = 0.0005), immunodeficiency (0.08,
p = 0.002), and higher serum lactate (0.08, p = 0.007).
The baseline concentration of presepsin was higher in
relation to the severity of organ dysfunctions, as denoted by
the SOFA score, and the number of prevalent organ dys-
functions or failures (Supplementary Fig. 1). Presepsin
concentration was significantly higher in patients with
bacterial infection (according to the site or blood culture)
than in those with negative culture or in those with no
culture available (Supplementary Table 1). Patients with
Gram-negative bacterial infections had higher levels of
presepsin than those with Gram-positive infections
(p = 0.02 for blood culture). Finally, patients with lung
infections had lower baseline presepsin levels than patients
with abdominal or urinary tract infections (p \ 0.0002).
Time course of presepsin and clinical course
during ICU stay
Higher presepsin on day 1 was associated with hemody-
namic instability during the first 24 h of treatment:
Table 1 Clinical characteristics according to baseline presepsin concentration
Characteristics All Presepsin
Tertile 1
(\597 ng/L)
Tertile 2
(597–1,397 ng/L)
Tertile 3
([1,397 ng/L)
P across
tertiles
n (%) 958 (100.0) 320 (33.4) 320 (33.4) 318 (33.2)
Presepsin–median [Q1–Q3] 946 [492–1,887] 388 [293–493] 949 [753–1,124] 2609
[1,901–4,310] –
Age, years 66.6 ± 14.7 63.8 ± 15.9 66.8 ± 14.7 69.2 ± 13.0 0.0002
Women, n (%) 395 (41.2) 129 (40.3) 134 (41.9) 132 (41.5) 0.92
Body mass index, kg/m2 26.4 ± 5.6 26.0 ± 5.4 26.8 ± 5.7 26.5 ± 5.6 0.19
Reason for admission to ICU, n (%)
Medical 540 (56.4) 191 (59.7) 166 (51.9) 183 (57.6) 0.12
Elective surgery 67 (7.0) 19 (5.9) 29 (9.1) 19 (6.0) 0.21
Emergency surgery 351 (36.6) 110 (34.4) 125 (39.1) 116 (36.5) 0.47
Preexisting conditions, n (%)
Liver disease 14 (1.5) 4 (1.3) 4 (1.3) 6 (1.9) 0.75
COPD 120 (12.5) 42 (13.1) 40 (12.5) 38 (12.0) 0.90
Chronic renal failure 42 (4.4) 3 (0.9) 7 (2.2) 32 (10.1) \0.0001
Immunodeficiency 124 (12.9) 26 (8.1) 49 (15.3) 49 (15.4) 0.007
Congestive or ischemic heart disease 164 (17.1) 45 (14.1) 55 (17.2) 64 (20.1) 0.13
SAPS II score 46 [35–56] 38 [31–48] 46 [36–56] 53 [44–63] \0.0001
Physiological/laboratory variables
Heart rate, beats/min 103.8 ± 20.8 100.9 ± 20.2 105.6 ± 21.0 105.0 ± 20.9 0.0076
Mean arterial pressure, mmHg 74.6 ± 15.0 77.7 ± 14.8 74.9 ± 14.4 71.2 ± 14.9 \0.0001
Mean arterial pressure after 6 h, mmHg 78.3 ± 13.4 81.3 ± 12.5 79.3 ± 13.8 74.3 ± 13.0 \0.0001
Central venous pressure, mmHg 9.9 ± 4.6 9.5 ± 4.4 9.6 ± 4.6 10.8 ± 4.9 0.0003
PaO2/FiO2 2.14 ± 1.14 2.17 ± 1.11 2.11 ± 1.18 2.13 ± 1.12 0.51
Urine output, mL/h 75.8 ± 70.2 88.1 ± 70.8 83.1 ± 74.1 56.1 ± 60.8 \0.0001
Lactate, mmol/L 3.2 ± 2.7 2.5 ± 2.1 3.3 ± 2.9 3.8 ± 3.0 \0.0001
Serum albumin, g/L 24.4 ± 6.2 25.6 ± 6.5 24.0 ± 6.0 23.7 ± 6.1 0.0005
Hemoglobin, g/dL 10.9 ± 2.0 11.4 ± 2.1 10.9 ± 1.9 10.5 ± 1.8 \0.0001
Serum creatinine, mg/dL 1.97 ± 1.62 1.23 ± 0.87 1.82 ± 1.45 2.88 ± 1.91 \0.0001
White blood cells, 103/mm3 13.2 ± 9.5 13.7 ± 8.4 12.1 ± 9.4 13.9 ± 10.6 0.0078
Central venous oxygen saturation, % 72.6 ± 9.8 73.1 ± 8.9 72.7 ± 10.0 72.0 ± 10.4 0.58
Serum bilirubin (mg/dL) 1.38 ± 1.96 0.96 ± 0.87 1.18 ± 1.07 2.00 ± 3.03 \0.0001
Platelet count (109/L) 188.1 ± 130.1 215.7 ± 131.5 181.4 ± 117.9 167.0 ± 135.6 \0.0001
SOFA score 7.0 [5.0–10.0] 5.0 [4.0–7.0] 8.0 [5.0–9.0] 9.0 [7.0–11.0] \0.0001
Shock, n (%) 540 (56.4) 151 (47.2) 191 (59.7) 198 (62.3) 0.0002
Mechanical ventilation, n (%) 760 (79.3) 241 (75.3) 259 (80.9) 260 (81.8) 0.09
Randomized to albumin, n (%) 474 (49.5) 154 (48.1) 154 (48.1) 166 (52.2) 0.49
Positive blood culture, n (%) 271/852 (31.8) 62/276 (22.5) 88/290 (30.3) 121/286 (42.3) \0.0001
Antibiotics at the time of randomization, n (%) 898 (93.7) 297 (92.8) 307 (95.9) 294 (92.5) 0.14
Antibiotics 6 h after randomization, n (%) 954 (99.6) 318 (99.4) 320 (100) 316 (99.4) 0.48
Appropriateness of antibiotic therapy on day 1
according to site culture, n (%)
422/558 (75.6) 119/156 (76.3) 151/199 (75.9) 152/203 (74.9) 0.95
Appropriateness of antibiotic therapy on day 1
according to blood culture, n (%)
211/259 (81.5) 43/58 (74.1) 75/85 (88.2) 93/116 (80.2) 0.09
ICU mortality, n (%) 253 (26.4) 42 (13.1) 74 (33.4) 137 (43.1) \0.0001
90-day mortality, n (%) 369 (39.1) 78 (24.8) 107 (33.9) 184 (58.4) \0.0001
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patients with higher presepsin had a lower probability of
mean arterial pressure of at least 65 mmHg or lactate
lower than 2 mmol/L, and a greater probability of being
under vasoactive drugs (p \ 0.0001 for all, Supplemen-
tary Table 2). Higher presepsin on day 1 was closely
associated with a higher incidence of subsequent new
organ failures, as denoted by the respiratory, coagulation,
liver, and kidney organ components of the SOFA score
(Fig. 1).
There were no differences in circulating presepsin
concentrations through the first 7 days after enrollment in
patients randomized to albumin or to crystalloids (p for
time x treatment interaction = 0.40). Consequently, rel-
ative changes in presepsin concentration from enrollment
were not different in the two experimental arms on day 2
(p = 0.28) or on day 7 (p = 0.53), both in patients with
or without shock. Although presepsin concentration was
higher in patients with shock than in those without shock
at baseline [1,017 (553–2,128) ng/L, n = 540 vs. 793
(426–1,606) ng/L, n = 418, p \ 0.0001] and at sub-
sequent time points, the time course was similar (p for
time x shock interaction = 0.50).
Appropriateness of antibiotic therapy
Patients with increasing concentrations of presepsin over
the first 7 days were less likely to have received early
appropriate antibiotic therapy, based on the positivity of
either site or blood cultures, than those with decreasing
levels over time (Table 2). Presepsin concentration ten-
ded to decrease on day 7 in patients with negative blood
cultures [-17 (-47 to ?44) % vs. day 1, median (Q1–
Q3)] and in those with positive blood cultures and
appropriate antibiotic therapy [-18 (-53 to ?38) %],
whereas it increased in those with positive blood cultures
and inappropriate antibiotic therapy [?24 % (-11 to
?199 %), p = 0.002 by Kruskal–Wallis test, Supple-
mentary Fig. 2a]. Similar trends were seen for site
cultures [-15 (-49 to ?41), -19 (-49 to ?32), and ?5
Fig. 1 Baseline presepsin concentration according to the incidence
of new organ failures, defined as a change in each component
during the study period to 3 or 4 from a value of 0, 1, or 2 at
baseline. Number of patients with new organ-specific failures:
respiration (238, 44.7 % of those without organ-specific failure at
baseline), coagulation (186, 21.4 %), liver (57, 6.3 %), kidney
(157, 21.8 %), cardiovascular (173, 44.0 %). P across categories by
Kruskal–Wallis test. Number of patients without prevalent organ
failure by organ and by presepsin tertiles (all; tertile 1, tertile 2,
tertile 3): respiration (533; 188, 169, 176), coagulation (868; 303,
292, 273), liver (905; 320, 306, 289), kidney (720; 294, 255, 171),
cardiovascular (393; 164, 120, 109)
Table 2 Therapeutic procedures and changes in circulating presepsin concentrations over time
Therapeutic variables Relative changes in presepsin concentration (%, day 7–day 1)
Tertile 1 (\-38 %) Tertile 2 (-37 to ?15 %) Tertile 3 ([16 %) P for trend
across tertiles
Appropriateness of antibiotic therapy based on site cultures
Appropriate therapy on day 1, n (%) 115/145 (79.3) 108/143 (75.5) 99/148 (66.9) 0.02
Total patient-days, n (%) 803/1,542 (52.1) 763/1,514 (50.4) 732/1,583 (46.2) 0.001
Appropriateness of antibiotic therapy based on blood cultures
Appropriate therapy on day 1, n (%) 60/65 (92.3) 47/58 (81.0) 50/70 (71.4) 0.002
Total patient-days, n (%) 397/1,542 (25.7) 332/1,514 (21.9) 356/1,583 (22.5) 0.03
Activated protein C
For at least 2 days, n (%) 4 (1.7) 3 (1.3) 5 (2.1) 0.73
Total patient-days, n (%) 19 (1.2) 17 (1.1) 24 (1.5) 0.48
Tight glycemic control
For at least 3 days, n (%) 177 (74.4) 183 (76.6) 183 (76.6) 0.58
Total patient-days, n (%) 1,136 (73.7) 1,126 (74.4) 1,182 (74.7) 0.52
Corticosteroids
For at least 3 days, n (%) 98 (41.2) 71 (29.7) 100 (41.8) 0.88
Total patient-days, n (%) 562 (36.4) 408 (26.9) 564 (35.6) 0.66
Extracorporeal hemofiltration for sepsis
For at least 2 days, n (%) 8 (3.4) 5 (2.1) 8 (3.4) 0.99
Total patient-days, n (%) 34 (2.2) 23 (1.5) 32 (2.0) 0.72
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(-40 to ?83) %, respectively, p = 0.02, Supplementary
Fig. 2b].
Presepsin and clinical outcomes
Higher presepsin levels on day 1 were associated with
most of the tertiary outcomes assessed at post hoc anal-
yses in the ALBIOS trial. Patients with higher presepsin
on day 1 had a higher incidence of acute kidney injury
and renal replacement therapy during the study, a longer
ICU stay, longer mechanical ventilation and time to dis-
continuation of vasopressor or inotropic agents, as well as
a longer duration and a lower degree of resolution of the
primary infection (Supplementary Table 3).
Prognostic value of presepsin
The presepsin concentrations remained high over 7 days
in patients who died in the ICU but decreased in survivors
(p \ 0.0001 for interaction between time and survival,
Supplementary Fig. 3).
Higher presepsin levels on day 1 were associated
with subsequent mortality (Supplementary Fig. 4).
Adjusting for all potential clinical risk factors, presepsin
concentration on day 1 was significantly associated with
increased mortality in ICU or at 90 days, in all patients,
as well in the subgroup of patients with septic shock,
whereas in the subgroup without shock it was signifi-
cantly associated with increased ICU mortality only
(Table 3). Addition of presepsin on day 1 to a clinical
model that included all significant risk factors for
mortality improved the prognostic accuracy (area under
the ROC curve) in particular for patients with shock, as
well as the metrics of reclassification (integrated dis-
crimination improvement (IDI) or continuous category-
free net reclassification improvement (NRI), Supple-
mentary Table 4). This correct reclassification was
mainly driven by the non-event component of the NRI.
There was no significant interaction between presepsin
concentration on day 1 and treatment allocation (albu-
min or crystalloids) on ICU or 90-day mortality
(Supplementary Table 5).
Figure 2 shows the Kaplan–Meier survival curves for
ICU or 90-day mortality by tertiles of relative changes of
presepsin concentration from day 1 to day 2 or from
day 1 to day 7. There was a graded increase in the risk of
mortality across tertiles of changes (log rank test:
p B 0.0003). In adjusted logistic models, increases in
presepsin concentration over 2 or 7 days were indepen-
dently associated with ICU or 90-day mortality, with the
exception of 2-day changes and 90-day mortality in
patients with shock (Supplementary Table 6). The same
tendency was observed for patients with or without shock.
Discussion
In a preliminary study on a subgroup of 100 patients of the
ALBIOS trial, we previously observed that presepsin had a
better prognostic value than procalcitonin in patients with
severe sepsis or septic shock [16]. Here, in a larger cohort of
well-characterized contemporary patients, we found that
early presepsin concentration was mainly influenced by
advanced age, poor hepatic and renal functions, shock, and
impaired tissue perfusion (low mean arterial pressure and
hyperlactatemia). Moreover, high presepsin levels follow-
ing the first hours of fluid resuscitation were associated with
a greater hemodynamic instability, as indicated by a smaller
proportion of patients with stable mean arterial pressure
(C65 mmHg), or a greater need for vasoactive drugs. These
findings may explain the close relationship between pre-
sepsin and the number and degree of organ dysfunctions or
failures, indicated by the SOFA scores in all its compo-
nents. Presepsin concentrations were higher in patients with
lower blood platelets, suggesting a possible relationship
between this marker and coagulation disorders [23]. Even
though presepsin was higher in patients with shock than in
those with severe sepsis without shock, we observed only a
weak relation with the cardiovascular component of the
SOFA score, based on mean arterial pressure and on the
doses of vasopressor drugs administered. Presepsin appears
therefore to be a good marker of the host response in a
variety of its clinical manifestations, encompassing several
organ-specific alterations.
The exact mechanisms of membrane CD14 expression
[24], presepsin release during sepsis, and its biological
function are still largely unknown. CD14 mediates the
response to a variety of PAMPs [7] with the simultaneous
release of a soluble fragment [25]. We found slightly
higher (ca. 25–30 %) levels of presepsin in patients with
bacterial infection than in those with negative or
unavailable culture. Soluble CD14 also recognizes bac-
terial patterns processed by the Toll-like receptor 2
complex (lipoteichoic acid and several lipoproteins), and
hence is not restricted to the identification of Gram-neg-
ative endotoxins [8]. Accordingly, presepsin may reflect
sepsis-induced immune host defense to microorganisms
and its consequences on organ function. At the same time,
it is worth noting that two of the strongest determinants of
higher circulating presepsin concentration were renal and
hepatic dysfunctions (high serum creatinine and biliru-
bin), suggesting that impaired plasmatic clearance may
also contribute to the elevated levels of the marker.
Immunodeficiency was more frequent in patients with
elevated presepsin levels. After adjustment for several
clinical covariates (age, severity of the overall disease,
number of organ dysfunctions) and for the presence of
immunosuppression, patients with higher presepsin had a
primary infection of longer duration, and a lower inci-
dence of resolution, irrespective of the type and site of
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infection. These results suggest that higher levels of
presepsin, independently of the severity and type of
infection per se, may indicate a loss of infection com-
partmentalization, or a state of immunoparalysis, leading
to a spreading of the related inflammatory reaction, and of
the innate immune host response, which may ultimately
lead to multiple organ failure and death. Interestingly,
CD14? monocytes have been recently considered
responsible for the development of immunosuppressive
activity through the production of interferon-gamma in
human umbilical cord matrix stem cells [26] or through
the IL-1b/prostaglandin E2 axis during pregnancy [27]. In
our study, we also found that presepsin levels predicted
the occurrence of new organ failures, thereby suggesting
that it may be a marker of this process, as previously
observed for soluble CD14 [28].
Though we did not design the present study to assess a
role for presepsin in guiding antibiotic therapy, we eval-
uated its time course in relation to the appropriateness of
first-line empirical antimicrobial treatment. We found that
monitoring presepsin for the first week of treatment may
be a good indicator of the adequacy of the antimicrobial
therapy. Indeed, patients with decreasing levels of pre-
sepsin over 7 days in ICU were more likely to have
received an early appropriate first-line empirical antibi-
otic therapy on day 1 than those with increasing levels (92
vs. 71 %). Changes in presepsin levels were also associ-
ated with the duration of appropriate antibiotic therapy, as
estimated by blood or site culture. Interestingly, most of
the inappropriate empirical antibiotic therapy was related
to infections caused by multidrug-resistant Gram-negative
bacteria. These findings suggest that measuring presepsin
may help not only in risk stratification after the diagnosis
of sepsis, but also in monitoring the efficacy of the
treatment employed, and in guiding its appropriateness.
We also found that presepsin measured on day 1
predicted mortality, independently of age, reasons for
ICU admission, SOFA score, hemodynamic and respira-
tory variables, laboratory markers, and appropriateness of
antibiotic therapy. The association was stronger in
patients with shock. Correct reclassification of the
patients was mainly driven by non-events, suggesting that
presepsin accurately lowered risk estimates for survivors.
Therefore, early assessment of presepsin may help in
identifying, among the most severe and fatal manifesta-
tions of sepsis, those states that are still reversible,
facilitating a more effective second-line and highly
intensive clinical treatments. Short-term increases in
presepsin concentrations predicted mortality.
In the ALBIOS trial, patients were randomized to
either albumin and crystalloids or crystalloids alone for
volume replacement [17]. Albumin replacement did not
improve survival at 28 and 90 days in the overall popu-
lation, but gave small, significant hemodynamic
advantages and was more effective in patients with septic
shock. In the present study, presepsin concentrations were
not significantly different in the two experimental arms,
and there was no interaction between median presepsin
concentration and randomized treatment on mortality.
Thus, in our experimental conditions, we could not find
any significant effect of correcting hypoalbuminemia on
presepsin levels.
The present study has some limitations. First, it did not
include all the patients enrolled in the ALBIOS trial, as
only a subgroup of the participating centers were involved
in the biomarker substudy. Nonetheless, these centers
Table 3 Presepsin concentration on day 1 and total mortality
Outcome Patients No. events/no. patients (%) OR [95 % CI] p
ICU mortality
All 253/958 (26.4) 1.77 [1.48–2.12] \0.0001
Severe sepsis 94/418 (22.5) 1.59 [1.23–2.05] 0.0004
Shock 159/540 (29.4) 2.29 [1.80–2.92] \0.0001
90-day mortality
All 369/945 (39.1) 1.77 [1.49–2.11] \0.0001
Severe sepsis 135/409 (33.0) 1.22 [0.92–1.63] 0.17
Shock 234/536 (43.7) 2.17 [1.66–2.69] \0.0001
OR [95 % CI] for an increment of 1 SD unit in log-transformed
concentration of presepsin. The covariates were introduced in the
multivariable logistic models if they had a p \ 0.20 at univariate
analyses. The following covariates were retained in the final models
after backward elimination. For ICU mortality, all patients: age,
body mass index, chronic obstructive pulmonary disease, immu-
nodeficiency, congestive or ischemic heart disease, reason for
admission in ICU, SAPS II score, appropriate antibiotic therapy,
PaO2/FiO2, platelet count, mechanical ventilation; for ICU mor-
tality, severe sepsis: age, immunodeficiency, heart rate, PaO2/FiO2,
platelet count, mechanical ventilation; for ICU mortality, septic
shock: age, chronic obstructive pulmonary disease, body mass
index, congestive or ischemic heart disease, PaO2/FiO2, platelet
count, mechanical ventilation. For 90-day mortality, all patients:
age, sex, body mass index, chronic obstructive pulmonary disease,
immunodeficiency, congestive or ischemic heart disease, reason for
admission in ICU, SAPS II score, appropriate antibiotic therapy,
PaO2/FiO2, platelet count, mechanical ventilation; for 90-day
mortality, severe sepsis: age, body mass index, mean arterial
pressure at baseline or after 6 h, chronic obstructive pulmonary
disease, chronic renal failure, immunodeficiency, SAPS II score,
SOFA score at baseline, appropriate antibiotic therapy, PaO2/FiO2,
platelet count, urine output; for 90-day mortality, septic shock: age,
sex, body mass index, chronic obstructive pulmonary disease,
congestive or ischemic heart disease, SAPS II score, appropriate
antibiotic therapy, PaO2/FiO2, platelet count
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enrolled the majority of the patients randomized in the
ALBIOS trial and also in the biomarker substudy, there-
fore guaranteeing a representativeness of the disease
investigated. Second, this analysis may have been
underpowered. Third, as the ALBIOS was a pragmatic
trial, the study protocol did not standardize the treatments
employed (with the exception of fluid management),
though they have been applied by the attending physicians
according to the current guidelines for the treatment of
severe sepsis and septic shock [29]. Fourth, the clinical
value of presepsin has not been compared with other
circulating biomarkers. Fifth, presepsin was not assessed
on a daily basis over 1 week, precluding a full evaluation
of its time course in the acute phase of sepsis.
Conclusions
The present study suggests that presepsin may be a good
candidate for accurate and timely prediction of abnormal
host response at an early stage before it becomes too
severe and jeopardizes survival. It also gives preliminary
indications that presepsin may be suited for monitoring
appropriate antibiotic therapy. Although no single circu-
lating marker is likely to be a panacea for the clinical
management of severe sepsis in view of its complexity
and rapid course, these findings are encouraging and
should prompt further validation of presepsin in different
clinical settings.
Acknowledgments The authors thank Giuseppe Cappelletti and
Alessandro Castelli (GEPA Srl, Bollate, Italy) for valuable help
with the presepsin assay.
Conflicts of interest SM, PC, RL, and LG received limited
research support from Mitsubishi Chemical Europe GmbH, the
manufacturer of the presepsin assay. RT is an employee at Mitsu-
bishi Chemical Europe GmbH; he had no access to raw data and did
not influence the analyses or drafting of the manuscript. The present
work was partially presented at EuroMedLab (Milan, May 2013)
and at the Annual Meeting of the American Association for Clinical
Chemistry (Chicago, July 2014).
Fig. 2 Changes in presepsin concentrations over time and ICU or
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